an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs—TTX-RIGA, an RNA–based agonist of the retinoic acid-inducible gene I (RIG-I)–driven ...
The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company ...